Human Insulin Market - Drugs (Biologics, Biosimilars), Type (Short Acting, Long Acting, Premixed), Brands (Lantus, NovoRapid, Humalog), Delivery Devices (Pens, Pen Needles, Syringes), Applications (Type 1 Diabetes, Type 2 Diabetes) - Forecasts to 2020

Published: January 2016
No. of Pages: 157
   

The global human insulin market is poised to reach ~USD 39.13 billion by 2020 growing at a CAGR of 8.1% from 2015 to 2020.North America is expected to hold the largest share of the global human insulin market in 2015.Market growth of human insulin products is being propelled by growing diabetes patient population, increasing population exposure to key risk factors leading to diabetes, rising market demand for human insulin analogs, technological advancements in the field of human insulin delivery devices, and favorable medical reimbursements. However, stringent regulatory requirements for product approval are restraining the growth of human insulin market. In addition, high product manufacturing costs is posing significant challenges for market growth during the forecast period.   

In this report, the global human insulin market is segmented on the basis of basis of products (human insulin biologics, insulin analogs & biosimilars, and delivery devices), drug type (rapid-acting, intermediate-acting, long-acting, short-acting, and premixed), drug brand (Lantus, NovoRapid/Novolog, Humalog, Humulin, Insuman, Actrapid, Insulatard, Mixtard, and Other Biosimilar Brands), delivery devices [insulin pens (reusable & disposable), pen needles (standard & safety), and conventional syringes], and applications (type I diabetes & type II diabetes).

Human insulin drugs segment is expected to account for the larger share of the global human insulin market in 2015, followed by insulin delivery devices. Significant demand growth for human insulin drugs during the next five years is owing to factors such as increasing market accessibility of generic human insulin products worldwide, rising government initiatives to support the development and commercialization of effective biosimilars, growing R&D for drug discovery & development, and rising proportion of aging population in developed countries.

Geographically, North America (comprising the U.S. and Canada)is expected to command the largest share of the global human insulin market in 2015, followed by Europe. Asia-Pacific is also poised to grow at the highest CAGR during the forecast period, owing to factors such as growing diabetes prevalence in APAC (coupled with large diabetic & pre-diabetic patient population), strengthening distribution networks of global product manufacturers in the region, evolving regulatory framework for marketing approvals & medical reimbursements, and rising public awareness related to benefits offered by human insulin in diabetes treatment (as compared to anti-diabetic drugs & animal derived insulin).

The global human insulin market is highly competitive, with various global as well as local players. In 2014, the global human insulin devices market was dominated by Sanofi (France), Novo Nordisk A/S (Denmark), and Eli Lilly and Company (U.S.), which together accounted for ~89.0% of the human insulin market. Geographic expansion, new product launches, agreements, collaborations, partnerships, awareness campaigns, and offering research fund & grants are the major strategies adopted by most market players to achieve growth in the global human insulin market.

Reasons to Buy the Report:

From an insight perspective, this research report has focused on various levels of analysis such as market share analysis of the top ten players and company profiles, which together comprise and discuss the basic views on the competitive landscape, emerging and high-growth segments of the human insulin market, and high-growth regions and their respective drivers, restraints, challenges, and opportunities.

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn help firms to garner higher market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the human insulin products offered by the top 10 players in the global market. The report analyzes the human insulin market by product, drug type, drug brand, delivery devices, and applications across key geographic regions
  • Product Development/Innovation: Detailed insights on upcoming human insulin products, product pipeline, research and development activities, and new product launches in the market
  • Market Development: Comprehensive information on lucrative emerging markets. The report analyzes the markets for various human insulin products across key geographic regions
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the global human insulin market
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of leading players in the global human insulin market

Human Insulin Market - Drugs (Biologics, Biosimilars), Type (Short Acting, Long Acting, Premixed), Brands (Lantus, NovoRapid, Humalog), Delivery Devices (Pens, Pen Needles, Syringes), Applications (Type 1 Diabetes, Type 2 Diabetes) - Forecasts to 2020

Table of Contents

1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Breakdown of Primaries
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions
2.4.1 Assumptions

3 Executive Summary
3.1 Introduction
3.2 Current Market Scenario
3.3 Future Outlook
3.4 Conclusion

4 Premium Insights
4.1 Global Market (2015–2020)
4.2 Global Market Size, By Product (2015)
4.3 Global HI Drugs Market Size, By Product Type (2015-2020)
4.4 Global HI Drugs Market Size, By Brand (2014)
4.5 Global HI Delivery Devices Market Size, By Type (2015-2020)
4.6 Global Market Size, By Region (2015-2020)

5 Market Overview
5.1 Introduction
5.2 Market Segmentation
5.3 Market Evolution
5.4 Market Dynamics
5.4.1 Key Market Drivers
5.4.1.1 Growth in the Number of Diabetic Patients
5.4.1.2 Increasing Population Exposure to Key Risk Factors Leading to Diabetes
5.4.1.3 Rising Market Demand for HI Analogs
5.4.1.4 Technological Advancements in HI Delivery Devices
5.4.1.5 Favorable Medical Reimbursement Scenario in Developed Countries
5.4.2 Key Market Restraints
5.4.2.1 Stringent Regulatory Requirements for Product Approval
5.4.3 Key Market Opportunities
5.4.3.1 Emerging Markets
5.4.3.2 Expected Patent Expiry of Key HI Drugs
5.4.4 Key Market Challenge
5.4.4.1 High Product Manufacturing Costs

6 Industry Insights
6.1 Introduction
6.2 Industry Trends
6.2.1 Growing Market Demand for HI Pens
6.2.2 Increasing Market Focus on the Pipeline Development of Novel Human Insulin Therapies
6.3 Pipeline Analysis
6.3.1 By Company
6.3.2 By Clinical Trial Phase
6.3.3 Porter’s Five Force Analysis
6.3.3.1 Threat From New Entrants
6.3.3.2 Threat From Substitutes
6.3.3.3 Bargaining Power of Buyers
6.3.3.4 Bargaining Power of Suppliers
6.3.3.5 Intensity of Competitive Rivalry

7 Global Human Insulin Market, By Product Type
7.1 Introduction
7.2 HI Drugs
7.3 HI Delivery Devices

8 Global Human Insulin Drugs Market, By Type
8.1 Introduction
8.2 Insulin Analogs and Biosimilars
8.2.1 Long-Acting Biosimilars
8.2.2 Rapid-Acting Biosimilars
8.2.3 Premixed Biosimilars
8.3 HI Biologics
8.3.1 Short-Acting Biologics
8.3.2 Intermediate-Acting Biologics
8.3.3 Premixed Biologics

9 Global Human Insulin Drugs Market, By Brand
9.1 Introduction
9.2 HI Analogs and Biosimilars
9.2.1 Lantus
9.2.2 Novorapid and Novolog
9.2.3 Humalog
9.2.4 Other Brands
9.3 HI Biologics
9.3.1 Actrapid, Mixtard, and Insulatard
9.3.2 Humulin
9.3.3 Insuman

10 Global Human Insulin Market, By Delivery Devices
10.1 Introduction
10.2 Syringes
10.3 Pens
10.3.1 Disposable Pens
10.3.2 Reusable Pens
10.4 Pen Needles
10.4.1 Standard Pen Needles
10.4.2 Safety Pen Needles

11 Global Human Insulin Market, By Application
11.1 Introduction
11.2 Type I Diabetes
11.3 Type II Diabetes

12 Human Insulin Market, By Region
12.1 Introduction
12.2 North America
12.2.1 U.S.
12.2.2 Canada
12.3 Europe
12.3.1 Germany
12.3.2 France
12.3.3 U.K.
12.3.4 Rest of Europe (RoE)
12.4 Asia-Pacific (APAC)
12.4.1 Japan
12.4.2 China
12.4.3 India
12.4.4 Rest of Asia-Pacific (RoAPAC)
12.5 Rest of the World (RoW)

13 Competitive Landscape
13.1 Overview
13.2 Market Share Analysis
13.2.1 HI Drugs Market
13.2.2 HI Delivery Devices Market
13.3 Competitive Scenario
13.4 Recent Developments
13.4.1 Geographical Expansions
13.4.2 Agreements, Collaborations, and Partnerships
13.4.3 New Product Launches
13.4.4 Awareness Programs
13.4.5 Funding & Scholarships
13.4.6 Strategic Acquisitions

14 Company Profiles
14.1 Introduction
14.1.1 Geographic Benchmarking
14.1.2 Strategic Benchmarking
14.1.2.1 Capacity Building
14.1.2.2 Product Development and Commercialization
14.2 B. Braun Melsungen AG
14.2.1 Business Overview
14.2.2 Product Portfolio
14.2.3 Recent Developments
14.3 Becton, Dickinson and Company
14.3.1 Business Overview
14.3.2 Product Portfolio
14.3.3 Recent Developments
14.4 Biocon Limited
14.4.1 Business Overview
14.4.2 Product Portfolio
14.4.3 MnM View
14.5 Biodel Inc.
14.5.1 Business Overview
14.5.2 Product Portfolio
14.5.3 Recent Developments
14.6 ELI Lilly and Company
14.6.1 Business Overview
14.6.2 Product Portfolio
14.6.3 Recent Developments
14.6.4 MnM View
14.7 Julphar (Also Known as Gulf Pharmaceutical Industries)
14.7.1 Business Overview
14.7.2 Product Portfolio
14.7.3 MnM View
14.8 NOVO Nordisk A/S
14.8.1 Business Overview
14.8.2 Product Portfolio
14.8.3 Recent Developments
14.8.4 MnM View
14.9 Sanofi
14.9.1 Business Overview
14.9.2 Product Portfolio
14.9.3 Recent Developments
14.9.4 MnM View
14.10 Wockhardt Limited
14.10.1 Business Overview
14.10.2 Product Portfolio
14.10.3 Recent Developments
14.11 Ypsomed AG
14.11.1 Business Overview
14.11.2 Product Portfolio
14.11.3 Recent Developments

15 Appendix
15.1 Insights of Industry Experts
15.2 Discussion Guide
15.3 Introducing RT: Real-Time Market Intelligence
15.4 Available Customizations
15.5 Related Reports

List of Tables

Table 1 Key HI Drugs: Year of Patent Expiry
Table 2 Key HI Therapies Under Pipeline Development & Commercialization: 2005-2015
Table 3 HI Pipeline: Major Companies Involved
Table 4 HI Pipeline: Stages of Clinical Trial
Table 5 Global Market Size, By Product Type, 2013–2020 (USD Million)
Table 6 Drugs Market Size, By Region, 2013–2020 (USD Million)
Table 7 Delivery Devices Market Size, By Region, 2013–2020 (USD Million)
Table 8 Global Drugs Market Size, By Type, 2013–2020 (USD Million)
Table 9 Global Insulin Analogs and Biosimilars Market Size, By Type, 2013–2020 (USD Million)
Table 10 Insulin Analogs and Biosimilars Market Size, By Region, 2013–2020 (USD Million)
Table 11 Long-Acting Insulin Analogs and Biosimilars Market Size, By Region, 2013–2020 (USD Million)
Table 12 Rapid-Acting Insulin Analogs and Biosimilars Market Size, By Region, 2013–2020 (USD Million)
Table 13 Premixed Insulin Analogs and Biosimilars Market Size, By Region, 2013–2020 (USD Million)
Table 14 Global Biologics Market Size, By Type, 2013–2020 (USD Million)
Table 15 Biologics Market Size, By Region, 2013–2020 (USD Million)
Table 16 Short-Acting HI Biologics Market Size, By Region, 2013–2020 (USD Million)
Table 17 Intermediate-Acting HI Biologics Market Size, By Region, 2013–2020 (USD Million)
Table 18 Premixed HI Biologics Market Size, By Region, 2013–2020 (USD Million)
Table 19 Global HI Drugs Market Size, By Product Type, 2013–2020 (USD Million)
Table 20 Global Insulin Analogs and Biosimilars Market Size, By Brand, 2013–2020 (USD Million)
Table 21 Insulin Analogs and Biosimilars Market Size, By Region, 2013–2020 (USD Million)
Table 22 Insulin Analogs and Biosimilars Market Size for Lantus, By Region, 2013–2020 (USD Million)
Table 23 Insulin Analogs and Biosimilars Market Size for Novorapid and Novolog, By Region, 2013–2020 (USD Million)
Table 24 Insulin Analogs and Biosimilars Market Size for Humalog, By Region, 2013–2020 (USD Million)
Table 25 Insulin Analogs and Biosimilars Market Size for Other Brands, By Region, 2013–2020 (USD Million)
Table 26 Global HI Biologics Market Size, By Brand, 2013–2020 (USD Million)
Table 27 HI Biologics Market Size, By Region, 2013–2020 (USD Million)
Table 28 HI Biologics Market Size for Actrapid, Mixtard, and Insulatard, By Region, 2013–2020 (USD Million)
Table 29 HI Biologics Market Size for Humulin, By Region, 2013–2020 (USD Million)
Table 30 HI Biologics Market Size for Insuman, By Region, 2013–2020 (USD Million)
Table 31 Global Market Size, By Delivery Device, 2013–2020 (USD Million)
Table 32 HI Syringes Market Size, By Region, 2013–2020 (USD Million)
Table 33 Global HI Pens Market Size, By Product Type, 2013–2020 (USD Million)
Table 34 HI Pens Market Size, By Region, 2013–2020 (USD Million)
Table 35 Disposable HI Pens Market Size, By Region, 2013–2020 (USD Million)
Table 36 Reusable HI Pens Market Size, By Region, 2013–2020 (USD Million)
Table 37 Global HI Pen Needles Market Size, By Product Type, 2013–2020 (USD Million)
Table 38 HI Pen Needles Market Size, By Region, 2013–2020 (USD Million)
Table 39 HI Standard Pen Needles Market Size, By Region, 2013–2020 (USD Million)
Table 40 HI Safety Pen Needles Market Size, By Region, 2013–2020 (USD Million)
Table 41 Global Market Size, By Application, 2013–2020 (USD Million)
Table 42 HI Application Market Size for Type I Diabetes, By Region, 2013–2020 (USD Million)
Table 43 HI Application Market Size for Type Ii Diabetes, By Region, 2013–2020 (USD Million)
Table 44 Market Size, By Region, 2013–2020 (USD Million)
Table 45 North America: Market Size, By Country, 2013–2020 (USD Million)
Table 46 U.S.: Market Size, By Product, 2013–2020 (USD Million)
Table 47 U.S.: Market Size , By Application, 2013–2020 (USD Million)
Table 48 Canada: Market Size, By Product, 2013–2020 (USD Million)
Table 49 Canada: Human Insulin Market Size , By Application, 2013–2020 (USD Million)
Table 50 Europe: Human Insulin Market Size, By Country, 2013–2020 (USD Million)
Table 51 Germany: Human Insulin Market Size, By Product, 2013–2020 (USD Million)
Table 52 Germany: Human Insulin Market Size , By Application, 2013–2020 (USD Million)
Table 53 France: Human Insulin Market Size, By Product, 2013–2020 (USD Million)
Table 54 France: Human Insulin Market Size , By Application, 2013–2020 (USD Million)
Table 55 U.K.: Human Insulin Market Size, By Product, 2013–2020 (USD Million)
Table 56 U.K.: Human Insulin Market Size , By Application, 2013–2020 (USD Million)
Table 57 RoE: Human Insulin Market Size, By Product, 2013–2020 (USD Million)
Table 58 RoE: Human Insulin Market Size , By Application, 2013–2020 (USD Million)
Table 59 APAC: Human Insulin Market Size, By Country, 2013–2020 (USD Million)
Table 60 Japan: Human Insulin Market Size, By Product, 2013–2020 (USD Million)
Table 61 Japan: Human Insulin Market Size , By Application, 2013–2020 (USD Million)
Table 62 China: Human Insulin Market Size, By Product, 2013–2020 (USD Million)
Table 63 China: Human Insulin Market Size , By Application, 2013–2020 (USD Million)
Table 64 India: Human Insulin Market Size, By Product, 2013–2020 (USD Million)
Table 65 India: Human Insulin Market Size , By Application, 2013–2020 (USD Million)
Table 66 RoAPAC: Human Insulin Market Size, By Product, 2013–2020 (USD Million)
Table 67 RoAPAC: Human Insulin Market Size , By Application, 2013–2020 (USD Million)
Table 68 RoW: Human Insulin  Market Size, By Product, 2013–2020 (USD Million)
Table 69 RoW: Human Insulin Market Size , By Application, 2013–2020 (USD Million)
Table 70 Geographical Expansions, 2012–2015
Table 71 Agreements, Collaborations, and Partnerships, 2012–2015
Table 72 New Product Launches and Product Approvals, 2012–2015
Table 73 Awareness Programs, 2012–2015
Table 74 Funding & Scholarships, 2012–2015
Table 75 Strategic Acquisitions, 2012–2015

List of Figures

Figure 1 Research Design
Figure 2 Bottom-Up Approach
Figure 3 Top-Down Approach
Figure 4 Data Triangulation
Figure 5 Assumptions for the Research Study
Figure 6 Human Insulin Market Share: Key Market Players (2014)
Figure 7 Future Trends: HI Drugs Market, By Type (2015–2020)
Figure 8 Future Trends: Human Insulin Market Size, By Brand (2015–2020)
Figure 9 Future Trends: HI Delivery Devices Market Size, By Type (2015–2020)
Figure 10 Future Trends: Human Insulin Market Share, By Region (2015–2020)
Figure 11 Attractive Growth Opportunities in the Human Insulin Market
Figure 12 North America is Expected to Dominate HI Drugs Market in 2015
Figure 13 Insulin Analogs & Biosimilars  Segment is Expected to Grow the Fastest During Forecast Period
Figure 14 Lantus Was the Best Selling Insulin Brand Across All the Key Geographies in 2014
Figure 15 Insulin Pens to Lead the Overall Growth in HI Delivery Devices Market Till 2020
Figure 16 Asia-Pacific is Poised to Be the Fastest Growing Region in Human Insulin Market Till 2020
Figure 17 Market Evolution of HI Products
Figure 18 Human Insulin Market: Drivers, Restraints, Opportunities, & Challenges
Figure 19 Growth in Diabetic Patient Population Across Key Who Regions (2000–2030)
Figure 20 Proportion of Geriatric Population, By Country (2012 vs 2020)
Figure 21 Global Trend in Government Healthcare Expenditure: Developed vs Developing Countries (2010–2012)
Figure 22 Porter’s Five Forces Analysis (2014): Increasing Number of New Product Manufacturers Increases Market Competition
Figure 23 Drugs to Cover the Largest Market Share of Human Insulin Market Till 2020
Figure 24 U.S. & Europe Lead, Globally, in Terms of the Number of Ongoing Human Insulin-Based Clinical Studies (2015)
Figure 25 Insulin Analogs and Biosimilars Market: Future Trends (2013-2020)
Figure 26 North America to Lead the Premixed Insulin Analogs Market Till 20202
Figure 27 APAC to Grow the Fastest in Human Insulin Biologics Market During the Forecast Period
Figure 28 Lantus to Lead the Insulin Analogs & Biosmilar Market Sales in 2014
Figure 29 Actrapd to Cover the Largest Market Share of Human Insulin Biologics Market in 2015
Figure 30 Insulin Pens Segment is Poised to Grow the Fastest Till 2020
Figure 31 Safety Needles Segment is Expected to Sitness Fastest Market Growth During the Forecast Period
Figure 32 Type 2 Diabetes Application is Poised to Be the Fastest Growing Human Insulin Market Segment During the Study Period
Figure 33 India Will Have Highest Diabetes Population in 2030
Figure 34 Market  Trends: North American Human Insulin Market (2015-2020)
Figure 35 Market Trends: European Human Insulin Market (2015-2020)
Figure 36 Market Trends: Asia-Pacific Human Insulin Market (2015-2020)
Figure 37 Leading Players Adopted the Strategy of Geographic Expansions to Strengthen Their Market Positioning During 2012 to 2015
Figure 38 Global Human Insulin Market Share, By Key Player (2014)
Figure 39 Global HI Drugs Market Ranking, By Key Player (2014)
Figure 40 Global HI Delivery Devices Market Ranking, By Key Player (2014)
Figure 41 Continuous Geographic Expansion is Stimulating Market Competition for Capacity Building Among Key Players
Figure 42 Geographic Revenue Mix of the Top 5 Market Players* (2014)
Figure 43 Leading Companies are Focusing on Capacity Building to Strengthen Their Product Development & Manufacturing Base
Figure 44 Leading HI Manufacturers are Focusing on Product Commercialization to Strengthen Their Market Position
Figure 45 B. Braun Melsungen AG: Company Snapshot
Figure 46 Becton, Dickinson and Company: Company Snapshot
Figure 47 Biocon Limited: Company Snapshot
Figure 48 ELI Lilly and Company: Company Snapshot
Figure 49 Julphar: Company Snapshot
Figure 50 NOVO Nordisk A/S: Company Snapshot
Figure 51 Sanofi: Company Snapshot
Figure 52 Wockhardt Limited: Company Snapshot
Figure 53 Ypsomed AG: Company Snapshot

Published By: MarketsandMarkets
Product Code: MarketsandMarkets1941


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we�ll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest: